| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3991676 | Journal of Thoracic Oncology | 2006 | 7 Pages |
Abstract
The combination of carboplatin and irinotecan is an active combination in NSCLC, with response rates comparable with other platinum-containing doublets. Further studies with irinotecan should incorporate prospective pharmacogenomic analysis to identify markers for response and toxicity.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Giancarlo A. MD, William L. MD, Kristin L. PharmD, MBA, Sharon Marsh, Feng PhD, Avinash BS, Kristopher MD, Howard L. PhD, Ramaswamy MD,